KANE BIOTECH INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.125 CAD | -3.85% |
|
-7.41% | +56.25% |
| Apr. 18 | Transcript : Kane Biotech Inc. - Special Call | |
| Apr. 15 | Kane Biotech Up 12% After Reporting Closing of STEM Animal Health Sale | MT |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 6.81 | 14.21 | 15.21 | 17.8 | 11.23 | 10.55 |
| Enterprise Value (EV) 1 | 7.834 | 13.59 | 16.47 | 21.37 | 16.99 | 19.06 |
| P/E ratio | -2.09 x | -12 x | -4.05 x | -3.79 x | -2.79 x | -2.02 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 13.5 x | 8.39 x | 11.3 x | 11.1 x | 4.21 x | 70.8 x |
| EV / Revenue | 15.5 x | 8.03 x | 12.3 x | 13.3 x | 6.37 x | 128 x |
| EV / EBITDA | -2.72 x | -4.09 x | -4 x | -4.51 x | -5.31 x | -5.89 x |
| EV / FCF | -4.24 x | -5.5 x | -5.58 x | -14.4 x | -6.61 x | -13.1 x |
| FCF Yield | -23.6% | -18.2% | -17.9% | -6.94% | -15.1% | -7.61% |
| Price to Book | -6.91 x | 17 x | -10.2 x | -4.58 x | -1.72 x | -1 x |
| Nbr of stocks (in thousands) | 80,114 | 101,532 | 108,614 | 114,814 | 124,830 | 131,845 |
| Reference price 2 | 0.0850 | 0.1400 | 0.1400 | 0.1550 | 0.0900 | 0.0800 |
| Announcement Date | 3/25/19 | 4/2/20 | 3/25/21 | 3/24/22 | 4/20/23 | 3/26/24 |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 0.5063 | 1.694 | 1.342 | 1.608 | 2.668 | 0.149 |
| EBITDA 1 | -2.885 | -3.323 | -4.12 | -4.733 | -3.2 | -3.234 |
| EBIT 1 | -2.957 | -3.377 | -4.185 | -4.817 | -3.364 | -3.35 |
| Operating Margin | -584.04% | -199.4% | -311.93% | -299.63% | -126.06% | -2,248.93% |
| Earnings before Tax (EBT) 1 | -3.261 | -0.9602 | -3.846 | -4.85 | -3.824 | -4.562 |
| Net income 1 | -3.261 | -0.9602 | -3.717 | -4.605 | -3.89 | -5.034 |
| Net margin | -644.12% | -56.7% | -277.04% | -286.39% | -145.78% | -3,379.05% |
| EPS 2 | -0.0407 | -0.0117 | -0.0346 | -0.0409 | -0.0322 | -0.0396 |
| Free Cash Flow 1 | -1.849 | -2.471 | -2.951 | -1.482 | -2.571 | -1.45 |
| FCF margin | -365.14% | -145.91% | -219.96% | -92.19% | -96.36% | -973.13% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/25/19 | 4/2/20 | 3/25/21 | 3/24/22 | 4/20/23 | 3/26/24 |
1CAD in Million2CAD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 1.02 | - | 1.26 | 3.57 | 5.76 | 8.51 |
| Net Cash position 1 | - | 0.62 | - | - | - | - |
| Leverage (Debt/EBITDA) | -0.3551 x | - | -0.3068 x | -0.7543 x | -1.8 x | -2.631 x |
| Free Cash Flow 1 | -1.85 | -2.47 | -2.95 | -1.48 | -2.57 | -1.45 |
| ROE (net income / shareholders' equity) | -573% | 1,297% | -402% | 1,970% | 134% | 72.7% |
| ROA (Net income/ Total Assets) | -74.6% | -97.9% | -67.1% | -53.9% | -35.8% | -37.1% |
| Assets 1 | 4.37 | 0.9808 | 5.536 | 8.541 | 10.87 | 13.58 |
| Book Value Per Share 2 | -0.0100 | 0.0100 | -0.0100 | -0.0300 | -0.0500 | -0.0800 |
| Cash Flow per Share 2 | 0 | 0.0100 | 0.0100 | 0.0100 | 0.0100 | 0.0100 |
| Capex 1 | 0.01 | 0.02 | 0.03 | 0.19 | 0.01 | 0.01 |
| Capex / Sales | 1.6% | 1.41% | 2.03% | 11.61% | 0.47% | 6.19% |
| Announcement Date | 3/25/19 | 4/2/20 | 3/25/21 | 3/24/22 | 4/20/23 | 3/26/24 |
1CAD in Million2CAD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +56.25% | 12.04M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- KNE Stock
- Financials Kane Biotech Inc.
